<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">GLP-1 Receptor Agonists for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">cAMP/PKA</td>
<td>Increased cAMP activates CREB</td>
</tr>
<tr>
<td class="label">PI3K/Akt</td>
<td>[mTOR](/entities/mtor) activation</td>
</tr>
<tr>
<td class="label">ERK1/2</td>
<td>Synaptic plasticity</td>
</tr>
<tr>
<td class="label">AMPK</td>
<td>Mitochondrial biogenesis</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">Anti-apoptotic</td>
<td>Inhibits caspase-3 activation</td>
</tr>
<tr>
<td class="label">Anti-inflammatory</td>
<td>Reduces TNF-α, IL-1β, IL-6</td>
</tr>
<tr>
<td class="label">Mitochondrial</td>
<td>Enhances PGC-1α expression</td>
</tr>
<tr>
<td class="label">Synaptic</td>
<td>Promotes spine formation</td>
</tr>
<tr>
<td class="label">[Autophagy](/entities/autophagy)</td>
<td>Enhances clearance of misfolded proteins</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">EVOKE</td>
<td>III</td>
</tr>
<tr>
<td class="label">EVOKE Plus</td>
<td>III</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NBI-818</td>
<td>I/II</td>
</tr>
<tr>
<
<table class="infobox infobox-therapeutic">
<tr>
<th class="infobox-header" colspan="2">GLP-1 Receptor Agonists for Neurodegenerative Diseases</th>
</tr>
<tr>
<td class="label">Pathway</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">cAMP/PKA</td>
<td>Increased cAMP activates CREB</td>
</tr>
<tr>
<td class="label">PI3K/Akt</td>
<td>[mTOR](/entities/mtor) activation</td>
</tr>
<tr>
<td class="label">ERK1/2</td>
<td>Synaptic plasticity</td>
</tr>
<tr>
<td class="label">AMPK</td>
<td>Mitochondrial biogenesis</td>
</tr>
<tr>
<td class="label">Mechanism</td>
<td>Effect</td>
</tr>
<tr>
<td class="label">Anti-apoptotic</td>
<td>Inhibits caspase-3 activation</td>
</tr>
<tr>
<td class="label">Anti-inflammatory</td>
<td>Reduces TNF-α, IL-1β, IL-6</td>
</tr>
<tr>
<td class="label">Mitochondrial</td>
<td>Enhances PGC-1α expression</td>
</tr>
<tr>
<td class="label">Synaptic</td>
<td>Promotes spine formation</td>
</tr>
<tr>
<td class="label">[Autophagy](/entities/autophagy)</td>
<td>Enhances clearance of misfolded proteins</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">EVOKE</td>
<td>III</td>
</tr>
<tr>
<td class="label">EVOKE Plus</td>
<td>III</td>
</tr>
<tr>
<td class="label">Trial</td>
<td>Phase</td>
</tr>
<tr>
<td class="label">NBI-818</td>
<td>I/II</td>
</tr>
<tr>
<td class="label">PD MED</td>
<td>III</td>
</tr>
<tr>
<td class="label">exenatide-PD</td>
<td>II</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Half-life</td>
</tr>
<tr>
<td class="label">Exenatide</td>
<td>2.4h</td>
</tr>
<tr>
<td class="label">Liraglutide</td>
<td>13h</td>
</tr>
<tr>
<td class="label">Dulaglutide</td>
<td>4.7h</td>
</tr>
<tr>
<td class="label">Semaglutide</td>
<td>165h</td>
</tr>
<tr>
<td class="label">Drug</td>
<td>Company</td>
</tr>
<tr>
<td class="label">Tirzepatide</td>
<td>Eli Lilly</td>
</tr>
<tr>
<td class="label">Retatrutide</td>
<td>Eli Lilly</td>
</tr>
<tr>
<td class="label">Survodutide</td>
<td>Boehringer</td>
</tr>
</table>
Glp 1 Receptor Agonists For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
Glucagon-like peptide-1 (GLP-1) receptor agonists are a class of drugs originally developed for type 2 diabetes that have shown significant neuroprotective potential in neurodegenerative diseases["@hlscher2022"]. These agents cross the blood-brain barrier and activate GLP-1 receptors on [neurons](/entities/neurons) and glial cells, triggering intracellular signaling cascades that promote cell survival, reduce neuroinflammation, and enhance mitochondrial function. [@athauda2024]
The growing evidence for neuroprotective effects has led to extensive clinical testing in Alzheimer's disease (AD), Parkinson's disease (PD), and other neurodegenerative conditions["@athauda2024"]. [@femminella2024]
GLP-1 receptors are Class B G protein-coupled receptors (GPCRs) expressed throughout the central nervous system, including the [hippocampus](/brain-regions/hippocampus), cerebral [cortex](/brain-regions/cortex), basal ganglia, and hypothalamus. Activation triggers multiple signaling pathways: [@zhang2023]
Semaglutide is a once-weekly [GLP-1 receptor](/entities/glp1-receptor) agonist being evaluated in large-scale Phase III trials for Alzheimer's disease:
The EVOKE trials represent the largest GLP-1 agonist program in AD to date, testing whether semaglutide can slow cognitive and functional decline in early AD patients.
Liraglutide has been studied in multiple AD trials:
The GIVE Phase II trial evaluated dulaglutide in early AD patients, completing in 2023 with results pending publication.
Exenatide has shown the most promise in PD:
Key Finding: In the Phase II study, patients receiving exenatide showed improvements in motor scores (MDS-UPDRS) that persisted even after a 12-week washout period, suggesting disease-modifying effects.
Phase II trial in PD showed improvements in motor function and non-motor symptoms.
Semaglutide shows the highest brain penetration and longest half-life, making it the leading candidate for neurodegenerative disease treatment.
GLP-1 agonists may synergize with:
The study of Glp 1 Receptor Agonists For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
Related Analyses: